Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Hospitalization for PE or Proximal DVT [Day -14, Day 0]
- At least 18 years of age
Exclusion Criteria:
- Prior use of a DOAC or warfarin [Day -180, Day 0]
- Stage 4 or 5 chronic kidney disease or end-stage renal disease [Day -180, Day 0]
- Dialysis or renal transplant [Day -180, Day 0]
- Recent major or clinically relevant non-major bleeding [Day -180, Day 0]
- Cancer [Day -180, Day 0]
- Bypass surgery, obesity, or the use of a weight loss or appetite suppressor [Day -180, Day 0]
- Significant liver disease and coagulopathy [Day -180, Day 0]
- Use of CYP3A4 or P-gp inhibitors or inducers [Day -180, Day 0]
- Other indications for anticoagulation (atrial fibrillation or prosthetic heart valve) [Day -180, Day 0]
- Pregnancy or breastfeeding [Day -180, Day 0]
- Use of an antiplatelet [Day -180, Day 0]
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Rivaroxaban
Reference group
|
Any rivaroxaban dispensing claim is used as the reference group
Other Names:
|
|
Apixaban
Exposure group
|
Any apixaban dispensing claim is used as the exposure group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative hazard of major bleeding or clinically relevant non-major bleeding events
Time Frame: Through study completion or censoring, up to 90 days
|
Claims-based algorithm: relative hazard of major bleeding or clinically relevant non-major bleeding events
|
Through study completion or censoring, up to 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative hazard of major bleeding
Time Frame: Through study completion or censoring, up to 90 days
|
Claims-based algorithm: relative hazard of major bleeding
|
Through study completion or censoring, up to 90 days
|
|
Relative hazard of clinically relevant non-major bleeding
Time Frame: Through study completion or censoring, up to 90 days
|
Claims-based algorithm: relative hazard of clinically relevant non-major bleeding
|
Through study completion or censoring, up to 90 days
|
|
Relative hazard of all-cause mortality
Time Frame: Through study completion, up to 90 days
|
Claims-based algorithm: relative hazard of all-cause mortality
|
Through study completion, up to 90 days
|
|
Relative hazard of recurrent VTE
Time Frame: Through study completion, up to 90 days
|
Claims-based algorithm: relative hazard of recurrent VTE
|
Through study completion, up to 90 days
|
|
Relative hazard of extracranial bleeding
Time Frame: Through study completion, up to 90 days
|
Claims-based algorithm: relative hazard of extracranial bleeding
|
Through study completion, up to 90 days
|
|
Relative hazard of intracranial bleeding
Time Frame: Through study completion, up to 90 days
|
Claims-based algorithm: relative hazard of intracranial bleeding
|
Through study completion, up to 90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shirley Wang, PhD, ScM, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Embolism and Thrombosis
- Embolism
- Thromboembolism
- Venous Thromboembolism
- Pulmonary Embolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Apixaban
Other Study ID Numbers
Other Study ID Numbers
- 2018P002966-DUP-COBRRA-VT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.